Oruka Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $4.2M | $14.1M | $12.3M | $7.1M | $5.6M | $2.9M | $1.1M | $2.3M |
| SG&A Expense | $3.9M | $4.6M | $4.3M | $4.4M | $4.1M | $4.0M | $3.2M | $5.0M |
| Operating Income | $-8.1M | $-18.7M | $-16.6M | $-11.5M | $-9.7M | $-6.9M | $-4.3M | $-7.4M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $8.0K | $6.0K | — | $4.0K | $3.0K | $4.0K | $3.0K | $5.0K |
| Pretax Income | $-8.0M | $-18.6M | $-16.4M | — | — | $-6.9M | $-4.3M | $-5.4M |
| Income Tax Expense | $-31.0K | $-61.0K | $0 | $0 | $0 | $0 | — | — |
| Net Income | $-7.9M | $-18.5M | $-16.4M | $-11.4M | $-9.7M | $-6.9M | $-4.3M | $-5.4M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-10.31 | $-1.77 | $-1.81 | $-1.82 | $-3.31 | $-0.52 | $-0.24 | $-0.40 |
| EPS (Diluted) | $-10.31 | $-1.77 | $-1.81 | $-1.82 | $-3.31 | $-0.52 | $-0.24 | $-0.40 |
| Shares Outstanding (Basic) | 773.6K | 11.8M | 9.1M | 9.1M | 20.5M | 17.3M | 17.8M | 13.4M |
| Shares Outstanding (Diluted) | 773.6K | 11.8M | 9.1M | 9.1M | 20.5M | 17.3M | 17.8M | 13.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |